Bank of New York Mellon
NPCE icon

Bank of New York Mellon’s Neuropace NPCE Stock Holding History

Bank of New York Mellon’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$921K Buy
57,977
+5,717
+11% +$92K ﹤0.01% 3414
2026
Q1 		$687K Sell
52,260
-1,587
-3% -$23.8K ﹤0.01% 3438
2025
Q4 		$831K Buy
53,847
+1,580
+3% +$21.1K ﹤0.01% 3340
2025
Q3 		$539K Buy
52,267
+302
+0.6% +$2.85K ﹤0.01% 3543
2025
Q2 		$579K Buy
51,965
+24,060
+86% +$301K ﹤0.01% 3431
2025
Q1 		$343K Sell
27,905
-1,437
-5% -$18K ﹤0.01% 3649
2024
Q4 		$328K Buy
29,342
+5,133
+21% +$44.6K ﹤0.01% 3734
2024
Q3 		$169K Sell
24,209
-9,850
-29% -$72K ﹤0.01% 3947
2024
Q2 		$257K Buy
+34,059
New +$344K ﹤0.01% 3875
2022
Q2 		– Sell
-17,875
Closed -$147K – 4670
2022
Q1 		$147K Hold
17,875
– – ﹤0.01% 4330
2021
Q4 		$180K Buy
17,875
+395
+2% +$5.13K ﹤0.01% 4307
2021
Q3 		$277K Buy
17,480
+5,981
+52% +$126K ﹤0.01% 4072
2021
Q2 		$274K Buy
+11,499
New +$267K ﹤0.01% 3991

Other funds holding NPCE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.21B AUM 82.36% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $598M AUM 32.4% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

Bank of New York Mellon's NPCE Position: Q2 2026 in Review

Bank of New York Mellon increased its Neuropace (NPCE) stake by 11% in Q2 2026, buying an estimated $92K and bringing the position to 57,977 shares worth $921K. The position accounts for ﹤0.01% of the portfolio, ranked #3414.

Bank of New York Mellon first reported a position in NPCE in Q2 2021 and has held it in 13 quarters since. 30 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Bank of New York Mellon held 57,977 shares of Neuropace worth $921K as of Q2 2026.
  • Bank of New York Mellon bought 5,717 Neuropace shares in Q2 2026, an estimated $92K.
  • Neuropace made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3414 holding.
  • Bank of New York Mellon first reported a position in Neuropace in Q2 2021 and has held it in 13 quarters since.
  • 30 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.